FamiCord AG Expands Stake in Stem Cell Banks

FamiCord AG, through its subsidiary Polski Bank Komórek Macierzystych (PBKM), has significantly expanded its presence in the European stem cell market. The company has acquired an additional 69% of shares in both Národní Centrum Pupečníkové Krve s.r.o. and Rodinná banka perinatálnych a mezenchymálnych buniek s.r.o. This boosts its stake from 26% to 95% in these family stem cell banks, which focus on cord blood and tissue processing in the Czech Republic and Slovakia respectively.

Primecell Advanced Therapy, retaining a 5% stake, will continue as a strategic partner. There's also an option for PBKM to acquire this minority share. Discussions are underway regarding potential collaboration in cell-based therapies across Europe, including intellectual property sharing.

The purchase agreement, valued in the mid-single-digit million euros, is expected to be finalized by June 2025. The impact of this acquisition on FamiCord's 2025 financial forecast is under review.